Journal
SCIENCE
Volume 328, Issue 5981, Pages 1031-1035Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1183057
Keywords
-
Categories
Funding
- National Cancer Institute of the NIH [CA104898, CA119414, CA119335, CA124427, CA115410, CA30199]
- U.S. Department of Defense [BC076050, BC08544]
Ask authors/readers for more resources
Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy. We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased vascular and tissue permeability in a tumor-specific and neuropilin-1-dependent manner, allowing coadministered drugs to penetrate into extravascular tumor tissue. Importantly, this effect did not require the drugs to be chemically conjugated to the peptide. Systemic injection with iRGD improved the therapeutic index of drugs of various compositions, including a small molecule (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab). Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available